Feng XC, Liu FC, Chen WY, Du J, Liu H. Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy. World J Gastrointest Oncol 2023; 15(4): 617-631 [PMID: 37123054 DOI: 10.4251/wjgo.v15.i4.617]
Corresponding Author of This Article
Hui Liu, MD, PhD, Chief Doctor, Professor, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, Shanghai 200082, China. liuhuigg@hotmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Apr 15, 2023; 15(4): 617-631 Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.617
Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy
Xiao-Chen Feng, Fu-Chen Liu, Wu-Yu Chen, Jin Du, Hui Liu
Xiao-Chen Feng, Fu-Chen Liu, Wu-Yu Chen, Jin Du, Hui Liu, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200082, China
Author contributions: Liu H constructed the idea of the article; Feng XC, Liu FC, Chen WY and Du J wrote the manuscript; Liu H, Feng XC and Liu FC revised the paper; Liu H provided financial support.
Supported byNational Natural Science Foundation of China, No. 81970453, and No. 82270634; and Shanghai Science and Technology Innovation Action Plan Project, No. 20XD1405100.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Liu, MD, PhD, Chief Doctor, Professor, The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, Shanghai 200082, China. liuhuigg@hotmail.com
Received: December 4, 2022 Peer-review started: December 4, 2022 First decision: December 26, 2022 Revised: January 9, 2023 Accepted: March 8, 2023 Article in press: March 8, 2023 Published online: April 15, 2023
Abstract
Hepatocellular carcinoma (HCC) is a common malignant tumor that affecting many people's lives globally. The common risk factors for HCC include being overweight and obese. The liver is the center of lipid metabolism, synthesizing most cholesterol and fatty acids. Abnormal lipid metabolism is a significant feature of metabolic reprogramming in HCC and affects the prognosis of HCC patients by regulating inflammatory responses and changing the immune microenvironment. Targeted therapy and immunotherapy are being explored as the primary treatment strategies for HCC patients with unresectable tumors. Here, we detail the specific changes of lipid metabolism in HCC and its impact on both these therapies for HCC. HCC treatment strategies aimed at targeting lipid metabolism and how to integrate them with targeted therapy or immunotherapy rationally are also presented.
Core Tip: This review systematically summarizes the aberrant changes of lipid metabolism in hepatocellular carcinoma (HCC), and for the first time expounds the impact of lipid metabolism on HCC targeted therapy and immunotherapy. It vividly displayed the changes of lipid metabolism in HCC and the targets of some reagents by drawing figures, and summarized the impact of lipid metabolism related reagents on HCC targeted therapy and immunotherapy through table.
